EnteroMedics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The following report cites that the company conducts preclinical trials of their drugs on animals.
“As a result of the findings of our preclinical studies, we were able to refine the implant technique, demonstrate the biocompatibility of our Maestro System in animals and collect the data necessary to begin human clinical trials.” (Page 9) Read the full document.
EnteroMedics, Inc. is a clinical development stage medical device company that engages in the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. Its initial product Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The company was founded by Mark B. Knudson, Robert S. Nickoloff, Timothy R. Conrad, Katherine S. Tweden and Richard R. Wilson on December 19, 2002 and is headquartered in St. Paul, MN. [Source: MarketWatch]
Company Website: http://www.enteromedics.com